Save Your Skin Foundation

Save Your Skin Foundation

June 07, 2013 17:05 ET

Exciting News for Melanoma Comes Out of American Society of Clinical Oncology (ASCO) 2013 Annual Meeting

The Save Your Skin Foundation shares news from ASCO on drug information and treatment updates that patients can look forward to in the near future

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 7, 2013) - Coming out of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the Save Your Skin Foundation shares exciting new drug information and treatment updates for skin cancer.

"Currently, there is a pressing need for new therapy options for metastatic melanoma," says Kathleen Barnard, Founder, Save Your Skin Foundation. "The results from new studies and new therapies presented at this year's ASCO provide patients and caregivers with new hope."

The last few years have seen remarkable improvements in therapy options for melanoma. At ASCO 2012 early data was presented on immunotherapy agents targeting the PD1 pathway, and now, at ASCO 2013 impressive data on two PD1 blockers, as well as studies of other immunotherapeutic approaches to advanced melanoma were presented.

Also presented at ASCO this year was news of two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar (debrafenib) capsules and the first MEK-inhibitor Mekinist (trametinib) tablets, approved by FDA as single-agent therapies. The Save Your Skin Foundation is hoping for Canadian approval very soon.

Amgen also announced positive findings from a pivotal phase III trial showing the benefits of their new melanoma drug talimogene laherparepvec. Amgen also presented new data on Vectibix and blinatumomab.

Merck also announced data from a study evaluating Lambrolizumab, an investigational anti-PD1 antibody in patients with advanced melanoma.

In a June 6th article by Susan Beck, Executive Editor, Oncology, about data presented at ASCO 2013, she writes: "The discussant at the Clinical Science Symposium on PD1/PDL1 pathway immunotherapy, Dr. Walter Urba of the Providence Cancer Center (Portland, OR), summed up the stunning progress that has been made in immunotherapy for melanoma with the bold statement that 'immunotherapy is now the first-line treatment for metastatic melanoma regardless of mutation status'."

As this groundbreaking data continues to come out of ASCO 2013, the Save Your Skin Foundation compliments the news by continuing patient support and public awareness efforts. Earlier this month, the Foundation announced their partnership with MetaOptima Technolgoy Inc., to provide Canada and the United States with an award-winning free app, which helps users to receive daily notifications about the Ultra-Violet (UV) radiation levels and also offers sun safety tips. Users can also receive weather forecasts and tips on how to reduce the negative effects of long UV exposure. U.S National Weather service and the weather office of the government of Canada contribute the data. More information can be found at

About Melanoma in Canada

Every year, thousands of Canadians are diagnosed with melanoma, with the incidence of the disease increasing faster than that of any other cancer. Melanoma is a deadly form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. One in 74 men and 1 in 90 women are expected to develop melanoma during their lifetime; 1 in 284 men and 1 in 486 women will die of it. Melanoma is clearly visible on the skin, and 90 per cent of melanomas are caused by exposure to UV light, including tanning beds.

About the Save Your Skin Foundation

The Save Your Skin Foundation is a Canadian not-for-profit foundation. Through events and other initiatives, the Foundation focuses on: raising funds for education and awareness, providing emotional and financial support to those dealing with melanoma and non-melanoma skin cancers, and on supporting the ongoing research and treatment of skin cancer - especially melanoma. The Save Your Skin Foundation is a member of the Coalition Priorité Cancer au Québec. For further information, visit

Contact Information